Class summary at a glance.

Every drug in the gamma-Aminobutyric Acid-ergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $134.2Mcombined across class
Total Rx claims: 7.8M2.4M unique beneficiaries
Generic mfrs (active): 21across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Baclofen

Brand: FLEQSUVY · 7.8M Part D claims (CY24) · 2.4M beneficiaries · First FDA approval: 1988-07-21

21 generic mfrs 1 plans require PA Discontinued

Low NADAC$0.033

→

Avg plan cost$0.334

Part D spend $134.2M 10× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Baclofen Injection

Brand: Gablofen · — Part D claims (CY24) · First FDA approval: 2017-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.